ATE214924T1 - Verwendung von nebivolol als anti-atherogenisches mittel - Google Patents

Verwendung von nebivolol als anti-atherogenisches mittel

Info

Publication number
ATE214924T1
ATE214924T1 AT95942209T AT95942209T ATE214924T1 AT E214924 T1 ATE214924 T1 AT E214924T1 AT 95942209 T AT95942209 T AT 95942209T AT 95942209 T AT95942209 T AT 95942209T AT E214924 T1 ATE214924 T1 AT E214924T1
Authority
AT
Austria
Prior art keywords
atherogeneic
nebivolol
agent
alpha
chromanmethanol
Prior art date
Application number
AT95942209T
Other languages
English (en)
Inventor
Anne Simone Josephine Lesage
Josepha Eduarda Maria F Leysen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE214924T1 publication Critical patent/ATE214924T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
AT95942209T 1994-12-28 1995-12-21 Verwendung von nebivolol als anti-atherogenisches mittel ATE214924T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203775 1994-12-28
PCT/EP1995/005174 WO1996019987A1 (en) 1994-12-28 1995-12-21 Use of nebivolol as an anti-atherogenic

Publications (1)

Publication Number Publication Date
ATE214924T1 true ATE214924T1 (de) 2002-04-15

Family

ID=8217503

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95942209T ATE214924T1 (de) 1994-12-28 1995-12-21 Verwendung von nebivolol als anti-atherogenisches mittel

Country Status (20)

Country Link
US (2) US5874461A (de)
EP (1) EP0801564B1 (de)
JP (1) JPH10511655A (de)
KR (1) KR100264348B1 (de)
CN (1) CN1167418C (de)
AT (1) ATE214924T1 (de)
AU (1) AU700364B2 (de)
CA (1) CA2207333C (de)
CZ (1) CZ287513B6 (de)
DE (1) DE69526120T2 (de)
DK (1) DK0801564T3 (de)
ES (1) ES2176354T3 (de)
FI (1) FI118884B (de)
HU (1) HU226208B1 (de)
NO (1) NO315687B1 (de)
NZ (1) NZ298074A (de)
PT (1) PT801564E (de)
SI (1) SI0801564T1 (de)
SK (1) SK282144B6 (de)
WO (1) WO1996019987A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100264348B1 (ko) * 1994-12-28 2000-08-16 디르크 반테 항-죽종형성제로서 네비볼롤을 함유하는 조성물
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
JP2000207219A (ja) * 1999-01-18 2000-07-28 Fujitsu Ten Ltd 車載端末とセンタ―との間の通信システム、及び、通信システムに使用する車載端末
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
DE60233140D1 (de) * 2001-05-02 2009-09-10 Nitromed Inc Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
EP1429756B1 (de) 2001-09-21 2006-11-22 Schering Corporation Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
WO2004042353A2 (en) * 2002-10-30 2004-05-21 Galileo Pharmaceuticals, Inc. Identifying therapeutic compounds based on their physical-chemical properties
JP2006508188A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
CA2580584C (en) * 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
HRP20080297T3 (en) 2004-07-30 2008-07-31 Torrent Pharmaceuticals Ltd Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
JP2008528626A (ja) * 2005-01-31 2008-07-31 マイラン ラボラトリーズ インク． ヒドロキシル化されたネビボロールを含む薬学的組成物
CA2610152C (en) 2005-06-01 2018-04-10 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EA019675B1 (ru) 2006-02-22 2014-05-30 Эдисон Фармасьютикалз, Инк. Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
EP3018122B1 (de) 2007-11-06 2018-10-10 BioElectron Technology Corporation 4-(p-quinonyl)-2-hydroxybutanamid-derivate zur behandlung von mitochondrialen erkrankungen
US20090181975A1 (en) * 2008-01-15 2009-07-16 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
BRPI0918139B1 (pt) 2008-09-10 2024-04-30 Ptc Therapeutics, Inc Composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos
CA2740773A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
MX2011006549A (es) * 2008-12-19 2011-07-20 Schering Corp Suplemento alimenticio para el cultivo de celula de mamifero y metodos de uso.
JP2012525399A (ja) 2009-04-28 2012-10-22 エジソン ファーマシューティカルズ， インコーポレイテッド トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療
CN103037839A (zh) * 2010-06-04 2013-04-10 全球药物科技有限公司 含有矫味剂的口服美其敏水性制剂
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
DE102014107132A1 (de) 2014-05-20 2015-11-26 Corden Pharma International Gmbh Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind
WO2016062285A1 (zh) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 神经系统疾病用药在制备抗癌医药组合物中的应用
WO2016100579A1 (en) 2014-12-16 2016-06-23 Edison Pharmaceuticals, Inc., Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
CN113024369A (zh) 2015-12-17 2021-06-25 Ptc医疗公司 用于治疗氧化应急障碍的化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337432C (en) * 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
KR100264348B1 (ko) * 1994-12-28 2000-08-16 디르크 반테 항-죽종형성제로서 네비볼롤을 함유하는 조성물

Also Published As

Publication number Publication date
DK0801564T3 (da) 2002-07-15
FI118884B (fi) 2008-04-30
SK85697A3 (en) 2000-04-10
SI0801564T1 (en) 2002-08-31
NO972980L (no) 1997-06-26
NO315687B1 (no) 2003-10-13
US6075046A (en) 2000-06-13
PT801564E (pt) 2002-09-30
DE69526120D1 (de) 2002-05-02
FI972793L (fi) 1997-06-27
CZ191997A3 (cs) 1999-01-13
CN1171739A (zh) 1998-01-28
DE69526120T2 (de) 2002-11-28
US5874461A (en) 1999-02-23
MX9704669A (es) 1997-09-30
AU700364B2 (en) 1999-01-07
CZ287513B6 (en) 2000-12-13
NO972980D0 (no) 1997-06-26
EP0801564A1 (de) 1997-10-22
CA2207333C (en) 2006-10-17
HUT77927A (hu) 1998-11-30
JPH10511655A (ja) 1998-11-10
HU226208B1 (en) 2008-06-30
KR100264348B1 (ko) 2000-08-16
SK282144B6 (sk) 2001-11-06
CA2207333A1 (en) 1996-07-04
NZ298074A (en) 2001-01-26
WO1996019987A1 (en) 1996-07-04
EP0801564B1 (de) 2002-03-27
ES2176354T3 (es) 2002-12-01
CN1167418C (zh) 2004-09-22
FI972793A0 (fi) 1997-06-27
AU4347796A (en) 1996-07-19

Similar Documents

Publication Publication Date Title
DE69526120D1 (de) Verwendung von nebivolol als anti-atherogenisches mittel
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE69713300D1 (de) Benzopyran derivate mit leukotrien-antagonistischer wirkung
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
ATE528279T1 (de) 3-butenyl-1-aminederivate und ihre verwendung als ih modulatoren von therapie für psychiatrische erkrankungen
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
ATE246924T1 (de) Neue therapeutische verwendung von nicergoline
EA199700243A1 (ru) Производное аминотетралина для лечения сердечно-сосудистых заболеваний
NO990450D0 (no) Behandling av sinnslidelser
NO984651D0 (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
DE59708511D1 (de) Verwendung von 7-(1-aminomethyl-2-oxa-7-aza-bicyclo 3.3.0]oct-7-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen
AU1569700A (en) Novel therapeutic application of low molecular weight heparin
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
TR200003352T2 (tr) Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler
FI972673A7 (fi) 4,4-(disubstituoitu)sykloheksan-1-oli-monomeereja ja vastaavia yhdiste itä
DK0820308T3 (da) Konjugat til behandling af inflammatoriske sygdomme
NO984198D0 (no) Fremgangsmåte for behandling av aggresjon
PT1133297E (pt) Nova aplicacao terapeutica da 1,6-dimetil-8beta-hidroximetil-10alfa-metoxiergolina
NO984190L (no) FremgangsmÕte for behandling av insomnia

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification